We are live on ! Find out more
PNT

POINT Biopharma Global Inc. Common Stock
PNT

Delisted

PNT was delisted on the 26th of December, 2023.

Back to rankings

130 hedge funds and large institutions have $571M invested in POINT Biopharma Global Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 49 increasing their positions, 32 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

94% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 16

53% more repeat investments, than reductions

Existing positions increased: 49 | Existing positions reduced: 32

25% more capital invested

Capital invested by funds: $455M → $571M (+$116M)

13% more funds holding

Funds holding: 115 → 130 (+15)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

90% less call options, than puts

Call options by funds: $70K | Put options by funds: $679K

Holders
130
Holders Change
+15
Holders Change %
+13.04%
% of All Funds
2.04%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.05%
New
31
Increased
49
Reduced
32
Closed
16
Calls
$70K
Puts
$679K
Net Calls
-$609K
Net Calls Change
-$674K

Top Buyers

Rank Fund Capital Flow
1
BG
Bellevue Group
Switzerland
+$11.1M
2
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans
Minnesota
+$8.48M
3
BlackRock
BlackRock
New York
+$7.65M
4
N
Nuveen
North Carolina
+$5.92M
5
JP Morgan Chase
JP Morgan Chase
New York
+$5.13M

Top Sellers

Rank Fund Capital Flow
1
RCMNY
Rubric Capital Management (New York)
New York
-$21.7M
2
PHS
PFM Health Sciences
California
-$16.8M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
-$10.5M
4
APM
Avidity Partners Management
Texas
-$6.52M
5
Citadel Advisors
Citadel Advisors
Florida
-$6.47M
Name Holding Trade Value Shares
Change 		Change in
Stake
AQR Capital Management
26
AQR Capital Management
Connecticut
$5.01M +$4.78M +542,148 +5,159%
Two Sigma Investments
27
Two Sigma Investments
New York
$4.21M +$2.69M +304,665 +190%
American Century Companies
28
American Century Companies
Missouri
$3.43M +$3.14M +356,261 +1,594%
VCIM
29
Velan Capital Investment Management
Georgia
$3.11M -$1.33M -151,200 -31%
Bank of New York Mellon
30
Bank of New York Mellon
New York
$2.98M +$708K +80,275 +32%
JAM
31
Jupiter Asset Management
United Kingdom
$2.86M +$2.03M +229,687 +264%
EHI
32
Eagle Health Investments
Connecticut
$2.77M +$2.7M +306,142 New
Janus Henderson Group
33
Janus Henderson Group
United Kingdom
$2.64M +$2.31M +262,162 +887%
Connor, Clark & Lunn Investment Management (CC&L)
34
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$2.45M +$1.8M +203,621 +305%
William Blair & Company
35
William Blair & Company
Illinois
$2.41M +$2.34M +265,530 New
Arrowstreet Capital
36
Arrowstreet Capital
Massachusetts
$2.2M +$2.14M +243,165 New
Charles Schwab
37
Charles Schwab
California
$2.19M +$89.9K +10,196 +4%
PAMP
38
Polar Asset Management Partners
Ontario, Canada
$2.15M – – –
Morgan Stanley
39
Morgan Stanley
New York
$1.85M +$442K +50,094 +33%
Rafferty Asset Management
40
Rafferty Asset Management
New York
$1.77M +$220K +24,909 +15%
Renaissance Technologies
41
Renaissance Technologies
New York
$1.73M -$888K -100,725 -35%
RCMNY
42
Rubric Capital Management (New York)
New York
$1.72M -$21.7M -2,455,336 -93%
Two Sigma Advisers
43
Two Sigma Advisers
New York
$1.47M +$983K +111,500 +218%
Bank of America
44
Bank of America
North Carolina
$1.43M -$2.04M -231,646 -60%
MAP
45
Moody Aldrich Partners
Massachusetts
$1.32M +$1.28M +145,442 New
RhumbLine Advisers
46
RhumbLine Advisers
Massachusetts
$1.31M +$280K +31,742 +28%
D.E. Shaw & Co
47
D.E. Shaw & Co
New York
$1.25M +$1.22M +138,174 New
Swiss National Bank
48
Swiss National Bank
Switzerland
$1.24M – – –
CSS
49
Cubist Systematic Strategies
Connecticut
$1.22M +$1.03M +116,275 +617%
BFS
50
Baskin Financial Services
Ontario, Canada
$1.21M -$92.6K -10,500 -7%
1
2
3 4 5

PNT Hedge Fund Activity: Q2 2023 in Review

130 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in POINT Biopharma Global Inc. Common Stock (PNT) for Q2 2023, worth a combined $571M — up 25% from $455M a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new PNT positions and 16 closed out — a net gain of 15 holders — while 49 added to existing stakes and 32 trimmed.

The largest buyer was Bellevue Group, opening a new position worth an estimated $11.1M. The largest seller was Rubric Capital Management (New York), cutting an estimated $21.7M.

  • 130 institutional investors held POINT Biopharma Global Inc. Common Stock (PNT) as of Q2 2023, up from 115 in Q1 2023.
  • Funds reported $571M of POINT Biopharma Global Inc. Common Stock stock for Q2 2023, up 25% quarter-over-quarter.
  • 31 funds opened new POINT Biopharma Global Inc. Common Stock positions in Q2 2023 and 16 closed out, a net change of +15 holders.
  • The largest POINT Biopharma Global Inc. Common Stock buyer in Q2 2023 was Bellevue Group, an estimated $11.1M added.
  • The largest POINT Biopharma Global Inc. Common Stock seller in Q2 2023 was Rubric Capital Management (New York), an estimated $21.7M sold.

Based on aggregated 13F filings for Q2 2023.